EDE makes UAE 3rd global market for Jascayd pulmonary fibrosis drug

Emirates Drug Establishment (EDE) approved Jascayd (nerandomilast) on 19 June 2026, making the UAE the third global market to clear the pulmonary fibrosis drug.

For hospital executives, the immediate issue is access: respiratory teams now have another oral option for adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), but local use still depends on formulary approval, payer rules and clinic capacity.

What EDE approved

Jascayd is a preferential phosphodiesterase-4B (PDE4B) inhibitor used to slow decline in lung function in adults with IPF and PPF. Gulf News reported the decision on 20 June 2026, citing EDE's review of quality, safety, efficacy and clinical data.

The UAE approval follows clearances in the United States and China. In the United States label, Jascayd is prescribed for adults with IPF and PPF and is taken orally. For UAE clinicians, the operational question is how fast local protocols move after EDE registration, because access depends on hospital pharmacy committees, insurance coverage and specialist prescribing rules.

"The UAE is the first country in the region and the third globally to approve Jascayd."
Emirates Drug Establishment, statement published 19 June 2026

Why operators should care

For medical directors, Jascayd is a pathway decision in 2026. IPF and PPF patients need baseline diagnosis, serial forced vital capacity testing and follow-up by respiratory specialists. EDE said early diagnosis and regular follow-up matter for chronic lung disease patients, which points to a practical gap in general hospitals where breathlessness may first enter cardiology, internal medicine or emergency pathways before an interstitial lung disease clinic sees the patient.

• Medical directors should review eligibility criteria, contraindications and monitoring rules for adult IPF and PPF patients.
• COOs should check whether pulmonary function testing capacity can support repeat measurements over 52 weeks or longer.
• CFOs should model formulary exposure before payer approval, because advanced respiratory medicines can shift outpatient pharmacy costs.
• CIOs should make sure EHR templates capture diagnosis, spirometry results, adverse events and prior antifibrotic use.

The regulatory chain is split across UAE healthcare in 2026. EDE regulates medicines at federal level. Facility licensing, clinical governance and insurance processes remain tied to Dubai Health Authority (DHA) in Dubai, Department of Health - Abu Dhabi (DOH) in Abu Dhabi and Al Ain, and Ministry of Health and Prevention (MOHAP) for the Northern Emirates. Operators will need to translate a national drug approval into emirate-level formulary and prior-authorisation workflows.

What to watch next

The approval gives pharmaceutical companies a sharper case for earlier UAE submissions when phase 3 data have already been reviewed by major regulators. For hospitals, it tests whether disease-specific clinics can document outcomes, manage adverse-event reporting and support payer negotiations for rare respiratory conditions.

The near-term implementation issue is patient identification in 2026. IPF and PPF are low-volume conditions, but they require high-resolution CT review, multidisciplinary discussion, pulmonary function testing and long-term monitoring. Hospitals with respiratory medicine, radiology and pharmacy committees under one governance structure should be able to move faster than facilities that rely on external referrals for imaging review and testing.

DHA, DOH and MOHAP operators should watch for payer rules on adult eligibility, prior therapies and renewal criteria in 2026. The number to remember is third globally: EDE's approval opens the door for Jascayd, but reimbursement, prescribing governance and diagnostic capacity will decide how quickly UAE patients receive it.